Juno Therapeutics Inc (NASDAQ:JUNO) – Equities research analysts at Wedbush issued their FY2022 earnings estimates for shares of Juno Therapeutics in a report issued on Wednesday. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will post earnings of ($0.71) per share for the year. Wedbush currently has a “Neutral” rating on the stock.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the previous year, the business earned ($0.57) earnings per share. The firm’s revenue was up 115.4% compared to the same quarter last year.
Juno Therapeutics (NASDAQ:JUNO) traded down $3.56 during mid-day trading on Friday, hitting $67.81. 5,220,193 shares of the stock were exchanged, compared to its average volume of 3,350,000. Juno Therapeutics has a twelve month low of $19.07 and a twelve month high of $74.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. The firm has a market capitalization of $7,740.00, a price-to-earnings ratio of -20.00 and a beta of 2.32.
Institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. increased its stake in Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the period. The Manufacturers Life Insurance Company increased its stake in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the period. State of Alaska Department of Revenue acquired a new position in Juno Therapeutics in the 4th quarter valued at approximately $173,000. Finally, QS Investors LLC bought a new stake in Juno Therapeutics in the second quarter worth approximately $135,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.
In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 270,250 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $46.17, for a total value of $12,477,442.50. Following the transaction, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Robert Azelby sold 1,816 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the transaction, the executive vice president now owns 70,832 shares in the company, valued at approximately $3,184,606.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 365,337 shares of company stock worth $17,540,499. Company insiders own 15.08% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.